Published in FINAL edited form as: Journal of Pharmacology and Experimental Therapeutics 323(2): 488-498 (2007)
INTRODUCTION
Increased permeability of the BBB is a pathological hallmark in several neurological disorders (Hawkins and Davis, 2005) . Neuroinflammatory events are associated with increased BBB breakdown and brain injury. Tumor necrosis factor-α (TNF-α) has been demonstrated to participate in the BBB opening, which follows cerebral ischemic injury (Yang et al., 1999) , sepsis (Tsao et al., 2001) , bacterial meningitis (Ramilo et al., 1990) , and human immunodeficiency virus type-1 (HIV-1) infection (Fiala et al., 1997) . TNF-α-mediated BBB breakdown is linked to the upregulation of matrix metalloproteinase (MMP) expression and activity (Rosenberg et al., 1995b) .
Metabolism of arachidonic acid through cyclooxygenase (COX) plays a key role in neuroinflammatory events (Hewett et al., 2006) . COX inhibition effectively blocked BBB permeability increases induced by rabbit IgG (#7074; Cell Signaling, Danvers, MA; 1:2000) or donkey anti-goat IgG Jackson ImmunoResearch Laboratories, West Grove, PA; 1:10,000) using SuperSignal ® West Pico Chemiluminescent substrate (Pierce, Rockford, IL). Each blot was stripped and reprobed with a rabbit antiactin IgG (Sigma-Aldrich, Saint Louis, MO; 1:7500) to confirm equal protein loading and transfer.
Quantification of the Western blots was performed using ImageJ software (National Institutes of Health; Bethesda, MD).
Tissue Processing for Immunohistochemistry
Twenty four hours after rhTNF-α or saline injection, rats were anesthetized with pentobarbital (50 mg/kg; i.p.), and transcardially perfused with cold phosphate buffered saline (PBS) followed by 2% PLP (2% paraformaldehyde, 0.1 M sodium periodate, 75 mM lysine in 100 mM sodium phosphate buffer at pH 7.4).
Brains were removed and immersed in 2% PLP overnight. The brains were cryoprotected in 30% sucrose in 2% PLP, placed in a Peel-A-Way ® histology mold (Ted Pella Inc., Redding, CA) containing Tissue-Tek ® embedding medium (Sakura Finetek, Torrance, CA), and frozen with 2-methylbutane cooled in liquid nitrogen. Brains were stored at -80°C until sectioned. Tissue was sectioned on a cryostat (Richard-Allan Scientific, Kalamazoo, MI), and SuperFrost ® /Plus slides (Fisher Scientific, Pittsburgh, PA) with 10 μm sections (5 sections per slide) were stored at -20°C until immunostaining was performed.
Double Immunofluorescence Labeling and Confocal Microscopy
Immunolabeling was performed for MMP-9, COX-2 and MMP-3. For investigating the cell types expressing each of these proteins following rhTNF-α injection, double immunolabeling was performed with specific cell markers, including glial fibrillary acidic protein (GFAP; marker of reactive astrocytes), neuron-specific nuclear protein (NeuN; marker of neurons) and OX-42 (also known as CD11b; marker of microglia/macrophages). Primary antibodies and dilutions used in the immunohistochemical analysis were:
rabbit anti-MMP-9 (AB19016; Chemicon International, Temecula, CA; 1:300), rabbit anti-COX-2 (160126;
Cayman Chemical, Ann Arbor, MI; 1:700), rabbit anti-MMP-3 (AB810; Chemicon International, Temecula, CA; 1:1000), mouse anti-GFAP (G3893; Sigma-Aldrich, Saint Louis, MO; 1:400), mouse anti-NeuN (MAB-377; Chemicon International, Temecula, CA; 1:400), and mouse anti-OX-42 (MAS370p; Accurate Chemical
Corp., Westbury, NY; 1:100). Secondary antibodies and dilutions were: goat anti-rabbit linked to orangefluorescent Alexa Fluor ® 546 dye (Cy3 filter) and goat anti-mouse labeled with Alexa Fluor ® 488 dye (FITC filter). Both secondary antibodies were obtained from Invitrogen (Carlsbad, CA) and diluted 1:500.
Double Immunofluorescence was performed as previously described (Yang et al., 2007) . Briefly, slides were dried for 30 min at 50°C followed by incubation with cold acetone for 5 min. This was followed by two immunofluorescence slides were also imaged confocally to verify co-labeling in a laser scanning confocal microscope (Zeiss LSM 510, Carl Zeiss Microimaging Inc., Thornwood, NY).
Magnetic Resonance Imaging (MRI)
For the MRI study, 8 rats were randomly divided into two groups: the first group consisting of 4 rats that received stereotaxic injection of rhTNF-α and treatment with indomethacin, while the second group of rats were injected with rhTNF-α, but instead, were treated with the vehicle (n=4). After 24 h, rats were transported to the MRI room, placed in a dedicated rat holder and moved to the isocenter of the magnet prior to the imaging session. MR imaging was performed on a 4.7T Biospec ® dedicated research MR scanner (Bruker Biospin, Billerica, MA), equipped with 500 mT/m (rise time 80-120 μs) gradient set (for performing small animal imaging) and a small bore linear RF coil (ID 72 mm) (Sood et al., 2007b) . Initial localizer images were acquired using the following parameters: 2D FLASH (Fast Low Angle SHot), TR/TE 10/3 ms, matrix 256 x 128, FOV 6.4 cm, 1 slice per orientation. After the localizer images were acquired, T2 weighted and diffusion weighted imaging (DWI) was performed with the following parameters; T2 , diffusion gradient along the slice select direction.
The slices containing the lesion were identified from the T2 weighted structural images and same slice location was prescribed for all the subsequent MR protocols. MR data for generating T2 maps was acquired using the following parameters: 2D MSME (Multi Slice Multi Echo), TR 3000, TE1 30 ms, TE2 60 ms, TE3 90 ms, TE4 120 ms, FOV 3.2 cm x 3.2 cm, slice thickness 2 mm, slice gap 1 mm, number of slices 2, matrix 64 x 64, number of averages 4, receiver bandwidth 100 kHz.
The MR protocol for acquiring data for the Patlak plot method was then implemented (Patlak et al., 1983) .
In this acquisition, a reference baseline acquisition using the fast T1 mapping protocol was obtained. Rats were injected 0.2 mmol/kg of gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA, MW= 938 Da;
Berlex, Montville, NJ) as a bolus into the femoral vein via an indwelling catheter, followed by imaging with rapid T1 mapping protocol, collecting 14 images over 45 minutes. The following optimized MR imaging parameters were used for this protocol: axial plane, 2D IR-SE-EPI, TR/TE 8s/19.4 ms, FOV 4.0 cm x 4.0 cm, slice thickness 2 mm, slice gap 1 mm, number of slices 2, matrix 64 x 64, number of averages 2, receiver bandwidth 250 kHz. Non slice selective magnetization inversion was performed using a hyperbolic secant (sech) RF pulse with pulse width 4 ms. The T1 mapping specific parameters for this protocol were; time for inversion (TI) TI = (100 + 600 x n) ms where n = 0, 1, 2, …12, number of TI points (n) is 13. The total scan time was 3 minutes and 12 seconds for each time point. The MR protocol parameters for rapid T1 mapping were optimized for accuracy of T1 relaxation time estimate in a single, normal rat brain (control) prior to including that animal in the study. The acquired data were transferred to a dedicated computer workstation for post processing. Post processing of the raw data involved generating Apparent Diffusion Coefficient (ADC) maps from DWI images, T2 maps, T1 maps from the raw data, reconstruction of permeability coefficient maps and construction of the Patlak plots.
All the data processing was performed using in-house software written in 64-bit MATLAB (Mathworks, Natick, MA) and implemented on a 64-bit processor (AMD64) workstation running Red Hat Enterprise 
Fluorometric Assay of Matrix Metalloproteinase-3 (MMP-3) Enzymatic Activity
The activity of MMP-3 (stromelysin-1) was measured fluorometrically using a 5-FAM/QXL™520 
Measurement of Reduced Glutathione (GSH)
Levels of GSH were determined in rat brain homogenates using the monochlorobimane (MCB) method (Kamencic et al., 2000) . MCB binds to GSH through interaction with glutathione-S-transferase (GST) to form a stable fluorescent adduct (MCB-GSH), allowing determination of GSH levels through fluorescent intensity of the MCB-GSH adduct. MCB has more selectivity for GSH over other thiols when compare with other bimanes, and was confirmed to react only with GSH (Fernandez-Checa and Kaplowitz, 1990). Brain homogenates (an aliquot from the homogenate prepared for zymography) containing 150 μg of protein were mixed, in duplicates, with the assay buffer (100 mM potassium phosphate buffer pH 6.5) containing 1 U/ml of GST from equine liver (BioVision, Mountain View, CA) and 0.5 mM of MCB (Sigma-Aldrich, Saint
Louis, MO) in a black 96-well plate. Samples were incubated in the dark for 30 min at 37°C. The fluorescent product formed was quantified using a spectrofluorometer (PerkinElmer Instruments, Model Figure 2A shows a series of T2 weighted images and color-coded permeability coefficient maps for two representative rats: rhTNF-α plus vehicle (top row) and rhTNF-α plus indomethacin (bottom row). The T2
weighted images demonstrated the lesion in relation to the anatomical detail in the rat brain. On the T2 maps, a 12% reduction in T2 values was observed on the ipsilateral lesion side in the indomethacin treated animals compared to the rhTNF-α plus vehicle group. There was no significant reduction in Apparent Diffusion Coefficient (ADC) values in the indomethacin-treated group compared to the rhTNF-α plus vehicle group. Permeability coefficient color maps showed a reduction below 1.0 x 10 -3 ml g -1 min -1 in the indomethacin treated group compared to over 3.0 x 10 -3 ml g -1 min -1 in the rhTNF-α plus vehicle group (note the scale differences). Figure 2B shows a graph of mean permeability coefficient values in rhTNF-α plus indomethacin group and rhTNF-α plus vehicle estimated using MRI. In the rhTNF-α plus vehicle group, the estimates in the ipsilateral and contralateral hemisphere were 5.47 ± 1.0 x 10 -3 ml g -1 min -1 and 0.38 ± 0.26 x 10 -3 ml g -1 min -1
, respectively. The permeability coefficient estimates in rhTNF-α plus indomethacin group were 0.41 ± 0.18 x 10 -3 ml g -1 min -1 and 0.31 ± 0.18 x 10 -3 ml g -1 min -1 in the ipsilateral and contralateral hemisphere, respectively. On applying one-way ANOVA test, there was a significant difference in permeability coefficient values between the groups. Furthermore, a significant difference (p<0.05) in the permeability coefficient values between the lesion and non lesion side in rhTNF-α plus vehicle rats was observed. However, the mean permeability coefficient estimates between the ipsilateral and contralateral side in rhTNF-α plus indomethacin rats were not significantly different. There was a significant (p<0.001) reduction observed in mean permeability coefficient values on the ipsilateral side in the indomethacin treated rats as compared to the untreated rats.
The dramatic increase in MMP-9 activity following rhTNF-α injection is reduced by indomethacin treatment
Intracerebral injection of 325 ng (5000 U) of rhTNF-α produced a significant increase in MMP-9 activity after 24 h compared with the saline-injected control, as revealed by gelatin zymography (Fig. 3A) .
Inhibition of COX with indomethacin produced a significant reduction in the gelatinolytic activity of MMP-9 (Fig. 3B) . No significant change in MMP-2 activity was observed in any of the treatment groups as compared to saline-injected animals.
Indomethacin limits the induction of MMP-9 protein expression following intracerebral injection of rhTNF-α
In our next experiments, we used immunoblotting to investigate the effect of indomethacin on the expression of MMP-9, MMP-2, COX-1 and COX-2 at 24 h following the injection of rhTNF-α into the rat striatum. MMP-9 protein levels increased dramatically in rhTNF-α-injected rats (Fig. 4A ). There was a significant reduction (p<0.05) in MMP-9 protein expression in animals injected with rhTNF-α and given indomethacin, as compared with vehicle-treated controls ( Fig. 4A and 4B ). In addition, the expression of COX-2 was significantly increased in the brain of rats injected with rhTNF-α when compared with saline injection ( Fig. 4A and 4C) . However, indomethacin treatment had no significant effect on rhTNF-α-mediated COX-2 induction (Fig. 4C) . Similar to the findings of the gelatin zymography analysis, rhTNF-α did not produce any increase in MMP-2 protein expression (Fig. 4D) , and indomethacin administration did not significantly affect MMP-2 protein levels ( Fig. 4A and 4D) . Furthermore, COX-1 expression was unaffected by rhTNF-α and did not change in rats administered indomethacin (Fig. 4 A and 4E ).
COX inhibition with indomethacin reduces rhTNF-α-induced MMP-3 protein expression and activity
Since stromelysin-1 (MMP-3) contributes to BBB disruption during lipopolysaccharide (LPS)-induced neuroinflammation (Gurney et al., 2006b), we investigated the effects of COX inhibition with indomethacin on MMP-3 expression. Rat pro-MMP-3 was detected by Western blot in its glycosylated form at approximately 62 kDa. Results from this experiment indicated that pro-MMP-3 expression is dramatically induced by rhTNF-α when compared to saline ( Fig. 5A and 5B). Very low levels of pro-MMP-3 were observed in saline-injected animals, and this was only observed when exposing the membrane to autoradiography film for longer periods of time (not shown). Treatment with indomethacin markedly reduced (p<0.05) pro-MMP-3 protein levels in comparison with TNF-α plus vehicle ( Fig. 5A and 5B).
Fluorescent enzymatic assay for MMP-3 activity showed a significant increase (p<0.01) in MMP-3 activity in the rhTNF-α plus vehicle group in relation to saline control, which was significantly (p<0.05) reduced by treatment with indomethacin (Fig. 5C ).
Cellular sources of MMP-9, MMP-3 and COX-2 following intracerebral injection of rhTNF-α
Since intracerebral injection of rhTNF-α produced a significant increase in MMP-9, MMP-3 and COX-2 levels, as revealed by the Western blot experiments (Figs. 4 and 5 ), we were interested in identifying the cellular source of these inducible proteins following rhTNF-α-mediated neuroinflammation. Double immunofluorescence labeling performed at 24 h showed that both, neurons (NeuN positive) and microglia/macrophages (OX-42 positive), were the cell types responsible for the enhanced MMP-9 production after rhTNF-α injection (Fig. 6A) . Very few GFAP-positive astrocytes were immunoreactive for MMP-9 in this model. Further inspection of these brain sections under a laser scanning confocal microscope confirmed that MMP-9-expressing cells were NeuN and OX-42 positive (Fig. 6A) . Double immunolabeling for MMP-3 and each specific cellular marker was conducted in saline-and rhTNF-α- (Fig. 6B) . A similar immunolabeling analysis was performed for COX-2. We observed COX-2 immunoreactivity in neurons and microglia/macrophages (not shown). Compared to rhTNF-α-injected brains, saline-injected controls showed very few cells positive for either MMP-9, MMP-3 or COX-2 (not shown).
Indomethacin prevented GSH depletion during rhTNF-α-mediated neuroinflammation
COX activity is an important source of oxidative stress during neuroinflammation (Candelario-Jalil et al., 2003b; Pepicelli et al., 2005; Akundi et al., 2005a) . In order to investigate the effects of indomethacin treatment on endogenous antioxidant capacity following rhTNF-α, we measured GSH levels in brain homogenates prepared from saline, rhTNF-α plus vehicle, and rhTNF-α plus indomethacin groups. A significant reduction in GSH was found in the rhTNF-α plus vehicle group in relation to saline-injected animals and indomethacin reversed rhTNF-α-induced GSH depletion (Fig. 7) .
DISCUSSION
Our results link MMPs to COX-mediated disruption of the BBB during TNF-α-induced neuroinflammation.
We have demonstrated for the first time that pharmacological inhibition of COX with indomethacin protects against BBB disruption. Indomethacin significantly attenuated the activity and expression of MMP-9 and MMP-3, and prevented the loss of GSH following intracerebral injection of TNF-α.
Other investigators have shown, in an in vitro model of the BBB that enhanced COX activity, with the concomitant increase in prostaglandin formation, is involved in TNF-α-mediated increase in permeability.
Inhibition of COX activity with indomethacin or with the COX-2 selective inhibitor NS-398 prevented TNF-α-induced changes in permeability (Mark et al., 2001a) .
A better understanding of the molecular mechanisms involved in TNF-α-mediated increase in MMPs could lead to the discovery of new potential targets amenable to pharmacological manipulation in order to limit BBB opening and brain edema in many neurological disorders. Earlier we showed that MMP-9 was induced by intracerebral injection of TNF-α (Rosenberg et al., 1995a) . MMP blockade with the MMP inhibitor, BB-94 (Batimastat), prevented the BBB breakdown seen at 24 h following TNF-α injection (Rosenberg et al., 1995c) , suggesting that enhanced MMP-9 activity is pivotal in BBB disruption. Present data extend those findings by demonstrating that increased BBB permeability induced by TNF-α appears to be linked to the increase in MMP-9 and MMP-3 through a COX-dependent mechanism. Furthermore, we 
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( Ting, 1990; Zuckerman et al., 1994; Candelario-Jalil et al., 2007f) , bacterial meningitis (Kadurugamuwa et al., 1989) , and against edema associated with brain tumors (Badie et al., 2003) .
The availability of selective inhibitors of the COX isozymes provides a powerful pharmacological tool to dissect the relative contribution of each isoform to the inflammatory process. By using this approach in the present study, we found that COX-1 seems to be more important than COX-2 in mediating TNF-α-induced BBB permeability changes. This finding is in contrast with results from our recent study in a rat model of focal cerebral ischemia, where COX-2 inhibition with nimesulide, but not COX-1 inhibition with VAS, potently reduced BBB breakdown in the ischemic cerebral cortex (Candelario-Jalil et al., 2007c) . The apparent discrepancies among our studies, in terms of which COX isoform is playing the most important role in BBB damage, could be possibly explained by the different animal models employed (ischemia versus TNF-α). In addition, in the focal ischemic model we found that COX-2 inhibition failed to reduce BBB disruption in the striatum, and no significant increase in PGE 2 levels were observed in the striatal homogenates prepared from ischemic animals as compared to sham controls (Candelario-Jalil et al., 2007d) . In our present study, TNF-α was injected intrastriatally, therefore we might speculate that the protective effect of COX-2 inhibition against BBB opening is region-specific. In an earlier study, we found that both COX isoforms contribute to oxidative damage and neurodegeneration in the hippocampus following a global cerebral ischemic event (Candelario-Jalil et al., 2003a) . Thus, it seems that the contribution of each COX isozyme to the neuroinflammatory process depends on the type of injury, brain region under study, and possibly other unknown factors.
It is interesting that, despite being upregulated by TNF-α, COX-2 does not seem to mediate BBB disruption induced by this pro-inflammatory cytokine. It is possible that it takes several hours for a catalytically active COX-2 protein to be present in the injected site. By then, most of the free arachidonic acid released by the TNF-α-induced PLA 2 activity has been metabolized by COX-1. In this particular scenario following acute injection of TNF-α, arachidonic acid metabolism through COX-1 seems to play a greater role than through COX-2. This notion is supported by our findings that COX-1, but not COX-2, inhibition significantly limits TNF-α-mediated BBB breakdown. However, the observation that indomethacin confers more protection than the COX-1 inhibitor VAS may suggest that the relative small contribution of COX-2 should not be ignored.
The differences we observed between ischemia-and TNF-α-induced BBB openings, in terms of which COX isoform is involved, may have important implications for the potential therapeutic use of COX inhibitors to limit the BBB opening in different clinical conditions. Non-selective COX inhibitors such as indomethacin might be useful in the management of BBB breakdown following inflammatory processes (e.g., bacterial meningitis), whereas in cerebral ischemia, a selective COX-2 inhibitor would be preferable (Candelario-Jalil et al., 2007e) . Thus, the present findings herein shed more light into the specific role of COX in brain injury, and might have relevance for the potential use of COX inhibitors in the treatment of neurological disorders associated with BBB disruption.
T2 maps provide a useful way of quantifying edema using MRI. A 12% reduction in T2 values from T2 maps in the indomethacin treated group suggests that there was a decrease in edema due to drug treatment. This could probably be explained by the anti-inflammatory action of indomethacin. The reduction in permeability coefficient values due to indomethacin treatment was found to be statistically significant (p<0.05) and confirms the findings from the 14 C-sucrose technique. This suggests that indomethacin may be working to reduce BBB leakage in the ipsilateral region and reiterates the BBB blocking effect of indomethacin and also suggests that indomethacin affects permeability on the ipsilateral side only and has no affect on the permeability in healthy tissue.
In summary, the present study provides compelling evidence implicating COX activity in the TNF-α-induced BBB disruption. Inhibition of COX with indomethacin prevented BBB opening through a mechanism which possibly involves reduction in MMP-3 and MMP-9 expression/activity and prevention of the loss of endogenous antioxidant capacity. This investigation adds significant information on the molecular mechanisms underlying the protection seen with COX inhibitors against BBB damage in several models of brain injury. Our results show for the first time that BBB disruption during neuroinflammation can be significantly reduced by administration of COX inhibitors. We propose that modulation of COX in brain injury by COX inhibitors or agents modulating prostaglandin E 2 formation/signaling may be useful in the clinical setting where the BBB is compromised by various pathologies. Fig. 1 . Effects of COX inhibitors on the uptake of 14 C-sucrose into rat brain as a measure of BBB permeability. Rats received an intrastriatal injection of 5000 U (325 ng) of rhTNF-α and were treated with either nimesulide (COX-2 inhibitor; 12 mg/kg, i.p., n=6), Valeroyl salicylate (VAS; COX-1 selective inhibitor; 20 mg/kg, i.p., n=6), indomethacin (non-selective COX inhibitor; 10 mg/kg, i.p., n=6) or the vehicle (5% Cremophor ® EL in saline, n=12). A control group included rats injected intracerebrally with saline and treated with the vehicle (n=8). Drugs were given immediately after rhTNF-α injection and again at 8 h. After 24 h of the rhTNF-α injection, rats were given 10 μCi of 14 C-sucrose intravenously and sacrificed 10 min later. Samples from striatum and blood were collected, and brain sucrose uptake was calculated as a percentage of sucrose in brain to that in blood (Sucrose Space in %). Indomethacin and VAS significantly reduced rhTNF-α-induced BBB disruption. **p<0.001 with respect to saline. # p<0.01 and *p<0.05 with respect TNF-α + vehicle. Representative gelatin zymogram showing the significant reduction by indomethacin of rhTNF-α-mediated increase in MMP-9 activity. Animals were injected in the striatum with either saline or 5000 U of rhTNF-α. Rats were treated with indomethacin (10 mg/kg, i.p., immediately after rhTNF-α and again after 8 h; n=6). Another group of animals was treated with the vehicle agent (n=6). Protein samples were analyzed by gelatin zymography to detect the presence of gelatinases at 24 h after rhTNF-α injection. B: Quantitative estimation of gelatinolytic activity of MMP-9 by gelatin zymography analysis. Densitometric and statistical analyses show increases in the activity of MMP-9 following rhTNF-α injection and a significant reduction in animals administered indomethacin. No significant increase in MMP-2 activity was found after rhTNF-α microinjection. Densitometric analysis of lytic zones at 72 kDa, corresponding to pro-MMP-2 activity, showed no significant changes among treatments (not shown). Bars represent mean ± S.E.M. of the 92-kDa band in arbitrary densitometric units. **p<0.05 with respect to saline. # p<0.05 with respect to the rhTNF-α plus vehicle group. Immunoblot analysis of protein levels of MMP-9, MMP-2, COX-2, COX-1 and actin in the rat brain after intracerebral injection of 325 ng of rhTNF-α (equivalent to 5000 U of TNF-α) or physiological saline. Animals were treated with the COX inhibitor indomethacin (10 mg/kg, i.p., immediately after rhTNF-α, and again after 8 h; n=6) or the vehicle agent (n=6). Protein extracts were prepared after 24 h of the injection with rhTNF-α, and subjected to SDS-PAGE followed by immunoblot analysis using specific antibodies. A: Representative Western blots for each protein in animals treated with saline, rhTNF-α plus vehicle, and rhTNF-α plus indomethacin. B-E: Quantitative densitometric analysis of relative protein expression normalized to actin loading control. Indomethacin significantly reduced MMP-9 expression induced by rhTNF-α. **p<0.05 with respect to MMP-9 expression in group injected with saline. # p<0.05 with respect to the rhTNF-α plus vehicle group. *p<0.05 with respect to COX-2 expression in salineinjected brains. Bars represent mean ± S.E.M. Western blot analysis of protein levels of pro-MMP-3 and actin in the rat brain after intracerebral injection of 325 ng of rhTNF-α or physiological saline. Animals were treated with the vehicle agent (n=6) or with the COX inhibitor indomethacin (10 mg/kg, i.p., immediately after rhTNF-α, and again after 8 h; n=6). Protein extracts were prepared after 24 h of the injection with rhTNF-α, and subjected to SDS-PAGE followed by immunoblot analysis using specific antibodies. Panel A shows representative Western blots for each protein in animals treated with saline, rhTNF-α plus vehicle, and rhTNF-α plus indomethacin. B: Quantitative densitometric analysis of relative protein expression normalized to actin loading control. Indomethacin significantly reduced rhTNF-α-induced pro-MMP-3 expression. Only very faint bands for active MMP-3 (~45 kDa) were seen by Western blot. These bands appeared after a relatively long exposure of the blot to the autoradiography film. This hampered the accurate quantification of these bands using densitometry due to enhanced background. Similarly, saline-injected brains showed faint pro-MMP-3 expression, which was seen only after extended exposure of the blot to X-ray film. C: Analysis of MMP-3 activity using a fluorescence resonance energy transfer (FRET) peptide. Significant increase of MMP-3 relative activity was seen in rhTNF-α-injected brains as compared with saline injection. Treatment with the COX inhibitor indomethacin significantly reduced rhTNF-α-induced MMP-3 activity in the 24-h brain lysates. **p<0.05 with respect to saline. Intracerebral injection of rhTNF-α produces a significant reduction in the levels of reduced glutathione (GSH) as compared to saline-injected control animals. Rats were treated with the vehicle agent (n=6) or with the COX inhibitor indomethacin (10 mg/kg, i.p., immediately after rhTNF-α, and again after 8 h; n=6). GSH levels were measured in brain homogenates after 24 h of the injection of rhTNF-α using the monochlorobimane (MCB) method. Homogenate extracts containing 150 μg of total protein were added to the assay buffer containing MCB and Glutathione-S-transferase and incubated for 30 min at 37°C in the dark. Formation of the MCB-GSH adduct was measured fluorometrically (Ex/Em=380/460 nm). Treatment with the COX inhibitor, indomethacin, prevented rhTNF-α-induced depletion of GSH. **p<0.05 with respect to saline. # p<0.05 with respect to the rhTNF-α plus vehicle group. Bars represent mean ± S.E.M.
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